Results 161 to 170 of about 23,896 (206)

“Refractory” Eosinophilic Airway Inflammation in Severe Asthma

American Journal of Respiratory and Critical Care Medicine, 2004
It has been suggested that patients with refractory eosinophilic airway inflammation represent a separate “eosinophilic” asthma phenotype associated with increased morbidity and a poor prognosis. To investigate whether persistent eosinophilia in these patients is a fixed feature or can still be modified by treatment, we investigated the effect of high ...
ten Brinke, A., Zwinderman, A. H., Sterk, P. J., Rabe, K. F., Bel, E. H.   +4 more
openaire   +2 more sources

Mepolizumab for eosinophilic severe asthma: recent studies

Expert Opinion on Biological Therapy, 2015
In September 2014 two large clinical studies of the anti-IL-5 monoclonal antibody mepolizumab in severe asthma were published in the New England Journal of Medicine (MENSA and SIRIUS).Eosinophilic inflammation has long been recognised as a feature of asthma.
Douglas S, Robinson, Harsha H, Kariyawasam   +1 more
openaire   +2 more sources

Histamine, Basophils and Eosinophils in Severe Asthma

Clinical Science, 1979
1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses.
T J, Charles, S J, Williams, A, Seaton, C, Bruce, W H, Taylor   +4 more
openaire   +2 more sources

Prognostic factors in severe eosinophilic asthma

Monitoring Airway Disease, 2018
Introduction: Uncontrolled Severe Eosinophilic Asthma (USEA) represents a challenging health problem. Characterize variables that predict poor control in this patients to will improve its management. The aim was identify the factors of poor control of severe eosinophilic asthma. Methodes: Were collected 78 patients of our Asthma Severe Unit.
Filipe Gonçalves Dos Santos Carvalho, Clara Padró Casas, María Basagaña Torrento, Marisa Rivera Ortun, María Del Mar Martínez Colls, Carlos Pollan Guisasola, Alicia Francoso Vicente, Eva Martínez Cáceres, Aina Teniente, Albert Roger, Juan Ruiz Manzano, Carlos Martinez Rivera   +11 more
  +6 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2013
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire   +2 more sources

Mixed Severe Eosinophilic and Allergic Asthma

The Singapore Family Physician, 2022
Difficult-to-treat asthma is asthma that is uncontrolled despite high intensity treatment. Patients with severe asthma are a subset of this group who remain uncontrolled despite addressing contributory factors, necessitating the use of add-on therapies including biologics. Currently available asthma biologics largely target type 2 inflammatory pathways
openaire   +1 more source

Eosinophils in the pathogenesis of paediatric severe asthma

Current Opinion in Allergy & Clinical Immunology, 2014
The importance and functional contribution of eosinophils to the pathogenesis of severe asthma was questioned when adult studies reported neutrophilic inflammation and Th17 cells were central to disease.Eosinophilic inflammation, atopic sensitization and airway remodelling are the hallmark features of severe asthma in children.
Sejal, Saglani, Clare M, Lloyd
openaire   +2 more sources

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Mara N, Poulakos, Shawna M, Cargill, Melissa F, Waineo, Allen L, Wolford   +3 more
openaire   +2 more sources

PERIPHERAL BLOOD EOSINOPHIL SHIFTS IN SEVERE, UNCONTROLLED ASTHMA

Annals of Allergy, Asthma & Immunology, 2018
Introduction Greater clarity is needed on peripheral blood eosinophil counts (BEC) associated with events such as exacerbations or responsiveness to biologics in severe asthma. Inclusion criteria and prespecified analyses on peripheral BECs vary between clinical trials. Stability of BEC on repeated measures in this population is unknown.
F Trudo, J Kreindler, N Lugogo, U Martin, B Cook, I Hirsch   +5 more
openaire   +1 more source

Mepolizumab in the Treatment of Severe Eosinophilic Asthma

Immunotherapy, 2015
IL-5 is crucial in the pathogenesis and evolution of eosinophilic asthma. Mepolizumab is a high-affinity humanized monoclonal antibody of the IgG1/k subtype that inhibits the binding of IL-5 to its receptor expressed on eosinophils, thereby inducing significant reduction in eosinophil circulation, as well as asthma exacerbations and corticosteroid ...
FAINARDI, Valentina, PISI, GIOVANNA, CHETTA, Alfredo Antonio   +2 more
openaire   +3 more sources